Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes
|
|
- Coral McGee
- 6 years ago
- Views:
Transcription
1 Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes A. A. Hussein,* C. J. Welty,* N. Ameli,* J. E. Cowan, M. Leapman,* S. P. Porten,* K. Shinohara* and P. R. Carroll, From the Department of Urology and UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California (AAH, CJW, NA, JEC, ML, SPP, KS, PRC), and Department of Urology, Cairo University, Cairo, Egypt (AAH) Purpose: We describe the outcomes of patients with low risk localized prostate cancer who were upgraded on a surveillance biopsy while on active surveillance and evaluated whether delayed treatment was associated with adverse outcome. Materials and Methods: We included men in the study with lower risk disease managed initially with active surveillance and upgraded to Gleason score 3þ4 or greater. Patient demographics and disease characteristics were compared. Kaplan-Meier curve was used to estimate the treatment-free probability stratified by initial upgrade (3þ4 vs4þ3 or greater), Cox regression analysis was used to examine factors associated with treatment and multivariate logistic regression analysis was used to evaluate the factors associated with adverse outcome at surgery. Results: The final cohort comprised 219 men, with 150 (68%) upgraded to 3þ4 and 69 (32%) to 4þ3 or greater. Median time to upgrade was 23 months (IQR 11e49). A total of 163 men (74%) sought treatment, the majority (69%) with radical prostatectomy. The treatment-free survival rate at 5 years was 22% for 3þ4 and 10% for 4þ3 or greater upgrade. Upgrade to 4þ3 or greater, higher prostate specific antigen density at diagnosis and shorter time to initial upgrade were associated with treatment. At surgical pathology 34% of cancers were downgraded while 6% were upgraded. Cancer volume at initial upgrade was associated with adverse pathological outcome at surgery (OR 3.33, 95% CI 1.19e9.29, p¼0.02). Conclusions: After Gleason score upgrade most patients elected treatment with radical prostatectomy. Among men who deferred definitive intervention, few experienced additional upgrading. At radical prostatectomy only 6% of cases were upgraded further and only tumor volume at initial upgrade was significantly associated with adverse pathological outcome. Key Words: watchful waiting, neoplasm grading, disease progression, prostatic neoplasms Abbreviations and Acronyms AS ¼ active surveillance BXn ¼ biopsy number after initial upgrade GS ¼ Gleason score PCa ¼ prostate cancer PSA ¼ prostate specific antigen PSAD ¼ PSA density PSM ¼ positive surgical margins RP ¼ radical prostatectomy Accepted for publication January 15, Study received institutional review board approval. Supported by the U.S. Department of Defense Prostate Cancer Research Program (W81XWH and W81XWH ). * Nothing to disclose. Financial interest and/or other relationship with Abbott Labs. Correspondence: Department of Urology, University of California, San Francisco, 1600 Divisadero St., Box 1695, San Francisco, California (telephone: ; FAX: ; pcarroll@urology. ucsf.edu). Financial interest and/or other relationship with NIH, Department of Defense, Myriad Genetics, AUA Update, Genomic Health and Medivation/Astellas. See Editorial on page 8. IN the contemporary PSA era the widespread use of PSA screening has contributed to an estimated reduction in prostate cancer mortality of 20% to 50%. 1,2 However, this has been at the expense of over diagnosis and subsequent overtreatment of cancers that may not have posed a significant threat to patients. Currently, although the American Urological Association and Editor s Note: This article is the second of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 268 and /15/ /0 THE JOURNAL OF UROLOGY 2015 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH,INC. Vol. 194, 85-90, July 2015 Printed in U.S.A. j 85
2 86 GLEASON GRADE PROGRESSION AND OUTCOMES National Comprehensive Cancer Network recommendations have been designed to limit over detection, neither prevent it. 3,4 The long natural history of PCa and detection of potentially indolent tumors have led to the development of active surveillance as an initial management strategy. AS for low risk disease allows postponing or avoiding the possible morbidities and adverse quality of life consequences that may be associated with treatment. Disease progression is actively monitored while maintaining an opportunity for cure. With time, more than a third of patients will be reclassified as at higher risk and pursue treatment. 5,6 In most cases reclassification to higher risk is due to upgrading at repeat biopsy. 7 Most cohorts use grade progression to Gleason scores 3þ4 or higher as a trigger for intervention and grade progression on serial biopsy is strongly associated with time to treatment. 8 It remains unclear which parameters, including grade progression, truly identify patients who need immediate, active treatment. Although most recommend active treatment in case of progression on repeat biopsies, some patients elect to continue on AS. In this context we describe the characteristics, followup and outcomes of patients who continued on AS in spite of grade progression on surveillance biopsy or sought treatment. PATIENTS AND METHODS Study Cohort This was a retrospective observational study of patients from the University of California at San Francisco Urologic Oncology Database conducted under institutional review board approval. We included consented men followed for at least 6 months after diagnosis with lower risk localized PCa (GS 3þ3 or lower at diagnosis and clinical T1 or T2 tumor) who were initially managed with AS. Additional inclusion criteria were a minimum of 6 cores taken at diagnostic biopsy, 33% or less positive and single core positivity 50% or less. We further restricted the analysis to include patients who further upgraded to GS 3þ4 or greater while on AS (fig. 1). AS Protocol The recommended AS regimen at our institution consisted of digital rectal examination, PSA testing at 3-month intervals and transrectal ultrasound guided prostate biopsies generally performed at 12 to 24-month intervals. Repeat biopsies included at least 14 cores taken from all sextants and included anterior gland sampling. Intervention was offered to men who experienced significant clinical or biopsy progression beyond the inclusion criteria. Statistical Analysis Patient demographics and disease characteristics were compared using means, medians and contingency tables with p values based on t-statistics, Wilcoxon signed rank test and chi-squared tests. Treatment after initial upgrade and adverse outcome (defined as having stage pt3a or greater and/or positive lymph nodes) among the subset of patients who underwent RP were used as the response variables. As PSM may be surgeon and technique dependent, a separate model for PSM as an adverse outcome was performed. We defined initial upgrade on any surveillance biopsy as an increase from GS 3þ3 or lower at diagnosis to 3þ4 or greater. We then categorized men with initial upgrade into 2 groups: 3þ4 and 4þ3 or greater. The first biopsy after initial upgrade was referred to as BX1, the second biopsy after initial upgrade as BX2, and so forth. The initial upgrade was used as the primary independent variable. Other covariates included in the model were age, PSAD, prostate volume and CAPRA (Cancer of the Prostate Risk Assessment) score risk classification at diagnosis, PSA before last biopsy or RP, time from diagnosis to initial upgrade, time from initial upgrade to RP and cancer volume (percentage of positive total cores and maximum of a single core positive) at initial upgrade. We also examined subsequent GS changes when compared to the initial upgrade defined as a further upgrade, downgrade, no change or benign. Biochemical failure was defined as achieving a PSA of 0.2 ng/ml or greater on 2 consecutive post-rp tests. We used Kaplan-Meier curves to estimate the probability of being treatment-free stratified by initial upgrade groups 3þ4 and 4þ3 or greater, and the log rank test to determine whether the difference between the 2 groups was statistically significant. Time was censored if the treatment event had not been observed for an individual. Cox proportional hazard regression analysis was used to examine factors associated with treatment. Multivariate logistic regression analysis was used to evaluate the effect of covariates on the probability of having adverse outcome at RP. Statistical analyses were performed using SASÒ software version 9.3. RESULTS A total of 525 men met the initial inclusion criteria. Mean age at diagnosis was 61.6 years (range 42 to 82) with median PSA 5.2 ng/ml (IQR 4.0e7.2). Most men were diagnosed with clinical stage T1 (70%) and low CAPRA score (91%). Median followup after diagnosis was 59 months (IQR 37e89). The final cohort for analysis comprised 219 (42%) men who experienced a GS upgrade on followup biopsy, of whom 150 (68%) were upgraded to 3þ4 and 69 (32%) upgraded to 4þ3 or greater. There were 26 men who had no subsequent biopsy or treatment at time of analysis (17 with pattern 3þ4 and 9 with 4þ3 or greater). Of these, 17 were followed with PSA and/or ultrasound and the remaining 9 did not have a followup visit after upgrading. Median time to the initial upgrade was 23 months (IQR 11e49). Demographics and tumor characteristics are shown in the supplementary table ( Among 133 men who had an initial upgrade to 3þ4, 43% (57) stayed on AS and underwent BX1. On
3 GLEASON GRADE PROGRESSION AND OUTCOMES 87 Figure 1. Natural history of 219 patients on AS who started with GS 3þ3 and upgraded to 3þ4 or higher on surveillance biopsy. UCSF, University of California, San Francisco. UODB, Urology Oncology Database at UCSF. BX1, 7 men experienced further upgrade, while 23 were downgraded. Of those who underwent BX1 53% (23) remained on AS and underwent BX2, while 2 additional men were upgraded and 14 were downgraded. Twelve men had BX3 (2 were upgraded, 5 were downgraded) and 6 underwent BX4 (4 were downgraded) (fig. 2). Among the 60 men who had an initial upgrade to 4þ3 or greater 18% (11) stayed on AS and had BX1, of whom 3 were further upgraded. Four men continued on AS to BX2, of whom 1 was further upgraded and only 1 had BX3 (fig. 2). Of the total cohort of 219 patients 74% (163) eventually sought treatment, 69% (113) of whom elected RP while 28% (46) received radiation based therapy, 1% (2) received cryotherapy and 1% (2) received androgen deprivation therapy. Treatment data were incomplete for 2 patients and, therefore, were excluded. Mean age at treatment was 66 years (range 48.0 to 86.4). Median time to treatment was 28 months (IQR 16e52) and did not differ by extent of Gleason upgrade (3þ4vs4þ3 or greater) at initial biopsy. Of the men who sought RP 64% had GS 3þ4 and 36% had 4þ3 or greater as the highest grade before treatment. Among the 163 men treated 77% (125) underwent intervention soon after the initial upgrade while 23% (38) were treated after a further period of AS. The treatment-free survival at 5 years was 22% after initial upgrade to 3þ4 and 10% after upgrade to 4þ3 or greater (log rank p¼0.0015, fig. 3). Cox proportional hazard regression analysis, modeling time to treatment, showed that men with
4 88 GLEASON GRADE PROGRESSION AND OUTCOMES Table 1. Cox proportional hazard regression analysis modeling time to treatment after initial GS upgrade to 3þ4 or higher Covariate HR 95% CI p Value Age at diagnosis e PSA before last biopsy or treatment (ng/ml/ml) e PSAD at diagnosis (ng/ml 2 ) e Prostate vol at diagnosis (cc) e Time to initial upgrade e Initial upgrade category (4þ3 or higher vs 3þ4) e CAPRA risk at diagnosis (intermediate vs low risk) e Figure 2. Changes in Gleason grade (relative to initial upgrade category) with surveillance biopsies among cases upgraded to pattern 3þ4 vs upgraded to 4þ3 or higher. UG, upgrade. DG, downgrade. initial upgrade to 4þ3 or greater were more likely to be treated compared to 3þ4 (HR 1.93, 95% CI 1.34e2.78, p¼0.0004). Higher PSAD at diagnosis (HR 1.43, 95% CI 1.04e1.97, p¼0.03) and shorter time to initial upgrade (HR 0.99, 95% CI 0.98e0.99, p¼0.004) were also associated with treatment (table 1). In a separate Cox model downgrading on surveillance biopsies was associated with lower risk of treatment (HR 0.09, 95% CI 0.03e0.27, p <0.0001). At RP Gleason score remained the same for 60%, was downgraded for 34% and upgraded for 7% compared to the highest preoperative GS (table 2). With regard to adverse outcome at RP, pt3 was observed in 27% of men in the 3þ4 group and 50% of the 4þ3 or greater group. Of the men 21% (16) in the 3þ4 group had PSM, including 9 with pt2 and 7 with pt3 disease. Of these, 50% were unifocal (range 1 to 2 locations) and the median length was 2 mm. Among cases upgraded to 4þ3 or greater 24% (8) had PSM, of which 3 had pt2 and 5 had pt3 Figure 3. Kaplan-Meier curves of treatment-free survival among 219 men who experienced initial Gleason upgrade to 3þ4 vs 4þ3 or higher (log rank p¼0.0015). disease (all were multifocal, range 2 to 4 locations) with median length of 4.5 mm. Only 1 patient in the 4þ3 or greater group had positive lymph nodes. At mean followup of 15 months 8% of our cohort who had RP experienced biochemical failure. On logistic regression analysis only cancer volume at initial upgrade (greater than 33% positive cores or greater than 50% positive on a single core compared to 33% or less positive cores and 50% or less positive on a single core) was significantly associated with adverse pathological outcome at RP (OR 3.33, 95% CI 1.19e9.29, p¼0.02, table 3). None of the patient and tumor characteristics was associated with PSM at RP (table 4). DISCUSSION Overtreatment of clinically insignificant PCa is a concern for early detection protocols. Previous studies have used variables such as clinical stage, Gleason grade, cancer volume, the number of positive biopsies and the extent of cancer in each core to estimate the risk of significant cancer, and thereby select patients with tumors amenable to AS. Of these, Gleason grade may offer the strongest prognostic value and informs the regard for grade progression as a critical event during AS, though a growing clinical experience with intermediate risk patients may question rigid inclusion criteria. 9e11 To evaluate the natural history of untreated grade progression we evaluated a cohort of men who experienced Gleason upgrading during AS. Among those with an initial upgrade pattern of 3þ4 40% were downgraded on biopsy on BX1 and 61% were downgraded on BX2. While for those with 4þ3 or greater at upgrade, 7 were downgraded at BX1 and 3 were upgraded. Of 163 men (74%) who sought treatment after upgrade 125 (77%) received intervention without further biopsy. The extent of Gleason upgrade (4þ3 or greater in comparison to 3þ4), shorter time to upgrade and PSAD at diagnosis were all significantly associated with receiving treatment after the initial upgrade. Gleason grade progression on serial biopsy has been shown to have the strongest association with time to treatment in our study as well as others. 9,10 In
5 GLEASON GRADE PROGRESSION AND OUTCOMES 89 Table 2. Surgical pathology for 111 men who underwent RP No. Initial Upgrade 3þ4 (%) No. Initial Upgrade 4þ3 or Greater (%) p Value Pathological T-stage: pt2 56 (73) 17 (50) 0.02 pt3 21 (27) 17 (50) Pathological N-stage (pn1): Yes 0 (0) 1 (3) <0.001 No 20 (26) 20 (59) Not evaluated 57 (74) 13 (38) Pos margins: Yes 16 (21) 8 (24) 0.98 No 61 (79) 26 (76) Extracapsular extension: Yes 18 (23) 17 (50) No 59 (77) 17 (50) Seminal vesicle involvement: Yes 4 (5) 2 (6) 0.88 No 73 (95) 32 (94) Surgical CAPRA:* Low (0e2) 47 (61) 10 (30) <0.001 Intermediate (3e5) 29 (38) 18 (55) High (6e12) 1 (1) 5 (15) Pathological GS:* Upgrade 7 (10) 0 (0) 0.04 Downgrade 9 (13) 28 (70) Unchanged 54 (77) 12 (30) Adverse outcome at RP (pt3a or greater and/or pn1): Yes 21 (27) 18 (53) No 56 (73) 16 (47) * Pathological GS was not identified for 1 patient treated with neoadjuvant androgen deprivation. addition, downgrading on surveillance biopsy was associated with lower risk of treatment. Previous reports have shown that the absence of cancer on the first surveillance biopsy was associated with lower risk of further progression. 12 Nevertheless, change in GS during surveillance may not always represent true disease progression but rather under detection at the time of initial biopsy. This could be due to differences in grading from pathologist assessment or, perhaps more likely, by initial under sampling, where smaller volumes of more aggressive disease may be missed on biopsy. 13 Promise in reducing the risk of under sampling may be held by improved sampling methods including the use of extended Table 3. Logistic regression modeling adverse pathological outcome, defined as greater than pt3a and/or positive lymph nodes in 111 men who underwent RP Covariate OR 95% CI p Value Age at diagnosis per 5-yr increment e PSAD at diagnosis e Time to initial upgrade e Time from initial upgrade to RP e Initial upgrade category 4þ3 or higher vs 3þ e Ca vol at initial upgrade (greater than 33% pos e cores or greater than 50% pos on single core vs 33% or less pos cores þ 50% or less pos on single core) Prostate vol at diagnosis e CAPRA risk at diagnosis (intermediate vs low) e Table 4. Logistic regression modeling positive surgical margins in 111 men who underwent RP Covariate OR 95% CI p Value Age at diagnosis per 5-yr increment e PSAD at diagnosis e Time to initial upgrade e Time from initial upgrade to RP e Initial upgrade category 4þ3 or higher vs 3þ e Ca vol at initial upgrade (greater than 33% pos e cores or greater than 50% pos on single core vs 33% or less pos cores þ 50% or less pos on single core) CAPRA risk at diagnosis (intermediate vs low) e Prostate vol at diagnosis e Patients with pt3a or greater disease and/or positive lymph nodes were excluded from analysis. patterns for surveillance biopsies, use of experienced uropathologists, anterior gland sampling and the use of image targeted biopsy. 14 To date none of the nomograms designed to predict indolent cancers has shown added benefit predicting grade progression at RP, limiting their usefulness in patient counseling and decision making. 15 Most of the men who sought treatment in our study underwent RP. Pathological outcomes did not appear to differ significantly from men with equivalent risk treated immediately. Only 6% were upgraded at surgery, a comparatively low proportion to studies of patients undergoing RP for newly diagnosed low grade disease, a difference which may be explained by the extended sampling of these men on followup biopsy. 16 In our analysis only biopsy tumor volume (greater than 33% of cores or greater than 50% of a single core) was associated with adverse outcome at RP. Despite the wide confidence interval (1.19e9.29) observed in our study, these findings appear to agree with prior reports suggesting that cancer volume may be associated with undetected high grade cancers. 13,17 Our findings are consistent with previous studies reporting no significant difference in the pathological outcome at RP or biochemical progression between low risk patients who had immediate RP vs those who deferred treatment. 18 Of our cohort 22% had PSM, which is similar to our larger RP cohort. We did not find a significant association between patient and disease characteristics and PSM. However, patients with higher upgrade category (4þ3 or greater vs 3þ4) and PSM tended to have multifocal and larger extent of PSM. Patel et al found that for localized PCa, preoperative PSA was the most important predictor of PSM at RP, in addition to higher body mass index and lower prostate weight. 19 On the other hand, biopsy GS did not have a significant impact on univariate or multivariate analyses. In limited followup the observed 8% biochemical failure rate in our study appears consistent with prior longitudinal series,
6 90 GLEASON GRADE PROGRESSION AND OUTCOMES yet is inadequate to draw any conclusions regarding the oncologic outcomes of these patients. Although this study contributes to the understanding of the natural history of grade progression for men on AS, it has several limitations. The retrospective design of the study and the limited sample size may limit the conclusions drawn from the study. We could not account for all factors that could influence decision making. Adverse outcome was defined in terms of pathological findings at RP rather than clinical end points. While pathological and preoperative factors have previously been shown to predict long-term outcomes, additional followup of this subset of patients will provide us with better estimates of disease specific and recurrence-free survival in the future. The findings of the current study raise the possibility that not all men who experience grade progression on AS need to be treated immediately. The majority of our patients who remained on AS did not have further grade progression and only 6% of our patients had progression on surgical pathology. Among this select group of patients, PSA kinetics and nomograms likely are not reliable enough to differentiate who needs treatment. 20 Multiparametric magnetic resonance imaging, and molecular and gene expression profiling of biopsy tissue appear to be promising tools to improve the differentiation between indolent and aggressive tumors, and may assist in identifying the subset of men who may benefit most from early treatment and those that can be put safely under surveillance. 21,22 CONCLUSIONS In this AS cohort most patients elected local treatment after upgrade. Upgrade to GS 4þ3 or greater, shorter initial time to upgrade and higher PSAD at diagnosis were associated with receiving treatment. While few men who initially deferred treatment remained on AS at the last followup, few experienced additional upgrading. Furthermore, most men who elected RP as treatment had a stable or downgraded GS on surgical pathology. Apart from cancer volume at initial upgrade, none of the patient or tumor characteristics was significantly associated with an adverse outcome at RP. With further development of new tools to determine the lethal potential of PCa, it may be safe to continue to follow men who experience GS upgrade. REFERENCES 1. Bray F, Lortet-Tieulent J, Ferlay J et al: Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010; 46: Hugosson J, Carlsson S, Aus G et al: Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: Mohler JL, Kantoff PW, Armstrong AJ et al: Prostate cancer, version J Natl Compr Canc Netw 2014; 12: Carter HB, Albertsen PC, Barry MJ et al: Early detection of prostate cancer: AUA guideline. J Urol 2013; 190: Sheridan TB, Carter HB, Wang W et al: Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol 2008; 179: Klotz L, Zhang L, Lam A et al: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: Klotz L: Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes. Curr Urol Rep 2012; 13: Carter HB, Walsh PC, Landis P et al: Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002; 167: Epstein JI, Walsh PC, Carmichael M et al: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: Cheng L, Poulos CK, Pan CX et al: Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. J Urol 2005; 174: Cooperberg MR, Cowan JE, Hilton JF et al: Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 2011; 29: Cary KC, Cowan JE, Sanford M et al: Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies. Eur Urol 2014; 66: Corcoran NM, Hovens CM, Hong MK et al: Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. BJU Int 2012; 109: Emiliozzi P, Maymone S, Paterno A et al: Increased accuracy of biopsy Gleason score obtained by extended needle biopsy. J Urol 2004; 172: Wang SY, Cowan JE, Cary KC et al: Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. BJU Int 2014; 114: E Freedland SJ, Kane CJ, Amling CL et al: Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology 2007; 69: Dong F, Jones JS, Stephenson AJ et al: Prostate cancer volume at biopsy predicts clinically significant upgrading. J Urol 2008; 179: van den Bergh RC, Steyerberg EW, Khatami A et al: Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer 2010; 116: Patel VR, Coelho RF, Rocco B et al: Positive surgical margins after robotic assisted radical prostatectomy: a multi-institutional study. J Urol 2011; 186: Iremashvili V, Burdick-Will J and Soloway MS: Improving risk stratification in patients with prostate cancer managed by active surveillance: a nomogram predicting the risk of biopsy progression. BJU Int 2013; 112: van den Bergh RC, Ahmed HU, Bangma CH et al: Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. Eur Urol 2014; 65: Haffner MC, De Marzo AM, Yegnasubramanian S et al: Diagnostic challenges of clonal heterogeneity in prostate cancer. J Clin Oncol 2015; 33: e38.
J Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More informationPublished Ahead of Print on April 4, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on April 4, 2011 as 10.1200/JCO.2010.32.8112 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.32.8112 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title The quantitative Gleason score improves prostate cancer risk assessment Permalink https://escholarship.org/uc/item/9wq7g6k5 Journal Cancer,
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationDong Hoon Lee, Ha Bum Jung, Seung Hwan Lee, Koon Ho Rha, Young Deuk Choi, Sung Jun Hong, Seung Choul Yang and Byung Ha Chung *
Jpn J Clin Oncol 2012;42(11)1079 1085 doi:10.1093/jjco/hys147 Advance Access Publication 17 September 2012 Comparison of Pathological Outcomes of Active Surveillance Candidates Who Underwent Radical Prostatectomy
More informationJ Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION
VOLUME NUMBER 20 JULY 10 2011 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Changes in Prostate Cancer Grade on Serial Biopsy in Men Undergoing Active Surveillance Sima P. Porten, Jared M. Whitson,
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationExpanded criteria for active surveillance in prostate cancer: a review of the current data
Review Article Expanded criteria for active surveillance in prostate cancer: a review of the current data Cameron Jones 1, Mina M. Fam 2, Benjamin J. Davies 2 1 University of Pittsburgh School of Medicine,
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationLong-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer
Published Ahead of Print on December 15, 1 as 1.1/JCO.1.55.119 The latest version is at http://jco.ascopubs.org/cgi/doi/1.1/jco.1.55.119 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationDong Hoon Lee, Kyo Chul Koo, Seung Hwan Lee, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong and Byung Ha Chung
Jpn J Clin Oncol 2013;43(5)553 558 doi:10.1093/jjco/hyt041 Advance Access Publication 11 April 2013 Low-risk Prostate Cancer Patients Without Visible Tumor (T1c) On Multiparametric MRI Could Qualify for
More informationThe Impact of MRI-TRUS Cognitively Targeted Biopsy on the Incidence of Pathologic Upgrading After Radical Prostatectomy
Original Article World J Nephrol Urol. 2018;7(1):12-16 The Impact of MRI-TRUS Cognitively Targeted Biopsy on the Incidence of Pathologic Upgrading After Radical Prostatectomy Ragheed Saoud a, Albert El-Haj
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationDepartment of Urology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.5.321 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.5.321&domain=pdf&date_stamp=2014-05-16
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationJ Clin Oncol by American Society of Clinical Oncology INTRODUCTION
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Active Surveillance in Younger Men With Prostate Cancer Michael S. Leapman, Janet E. Cowan, Hao G. Nguyen, Katsuto K. Shinohara, Nannette Perez,
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationDisease-specific death and metastasis do not occur in patients with Gleason score 6 at radical prostatectomy
Disease-specific death and metastasis do not occur in patients with at radical prostatectomy Charlotte F. Kweldam, Mark F. Wildhagen*, Chris H. Bangma* and Geert J.L.H. van Leenders Departments of Pathology,
More informationUnderstanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices
Understanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices Scott R. Hawken,* Paul R. Womble,* Lindsey A. Herrel, Zaojun Ye, Susan M. Linsell, Patrick M. Hurley,
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationHelping you make better-informed decisions 1-5
Helping you make better-informed decisions 1-5 The only test that provides an accurate assessment of prostate cancer aggressiveness A prognostic medicine product for prostate cancer. A common diagnosis
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationRisk Migration ( ct2c=high)
Risk Migration ( ctc=high) Prostate Cancer Over- Detection, but Selective Treatment Active Surveillance Peter R. Carroll, MD, MPH Department of Urology University of California, San Francisco February,
More informationValidation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System
Original Article Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System Ariel A. Schulman, MD 1 ; Lauren E. Howard, MS 2
More informationConceptual basis for active surveillance
Conceptual basis for active surveillance 1. Screening results in overdiagnosis 2. Clinically insignificant disease can be identified 3. All treatments have significant side effects and cost. 4. Delayed
More informationAssociation of [ 2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer
Association of [ 2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer Jeffrey J. Tosoian,*, Stacy Loeb,*, Zhaoyong Feng, Sumit Isharwal, Patricia Landis, Debra J. Elliot,
More informationElsevier Editorial System(tm) for European Urology Manuscript Draft
Elsevier Editorial System(tm) for European Urology Manuscript Draft Manuscript Number: EURUROL-D-13-00306 Title: Post-Prostatectomy Incontinence and Pelvic Floor Muscle Training: A Defining Problem Article
More informationjournal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract
The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,
More informationEarly Experience With Active Surveillance in Low-Risk Prostate Cancer Treated
www.kjurology.org http://dx.doi.org/.4/kju.4...67 Original Article Urological Oncology http://crossmark.crossref.org/dialog/?doi=.4/kju.4...67&domain=pdf&date_stamp=47 Early Experience With Active Surveillance
More informationSommerakademie Munich, June
Active surveillance: Shrinking the grey zone Sommerakademie Munich, June 30 2016 Active surveillance Overview of 20 year history Laurence Klotz, MD, CM Professor of Surgery Sunnybrook Heatlh Sciences Centre
More informationEarly outcomes of active surveillance for localized prostate cancer
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
More informationShort ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy
Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory
More informationPercent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory
More informationEUROPEAN UROLOGY 63 (2013)
EUROPEAN UROLOGY 63 (2013) 101 107 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Laurence Klotz on pp. 108 110 of this issue
More informationBJUI. Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis
BJUI BJU INTERNATIONAL Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis Ruslan Korets, Catherine M. Seager, Max S. Pitman, Gregory W. Hruby, Mitchell C. Benson and
More informationAdam Raben M.D. Helen F Graham Cancer Center
Adam Raben M.D. Helen F Graham Cancer Center Is the biopsy sample representative of the extent of the disease in your patient with clinically low-risk prostate cancer? BIOPSY RP registry (n=8095) 3+3=6
More informationState-of-the-art: vision on the future. Urology
State-of-the-art: vision on the future Urology Francesco Montorsi MD FRCS Professor and Chairman Department of Urology San Raffaele Hospital Vita-Salute San Raffaele University Milan, Italy Disclosures
More informationPathologists Perspective on Focal Therapy: The Role of Mapping Biopsies and Markers
Pathologists Perspective on Focal Therapy: The Role of Mapping Biopsies and Markers M. Scott Lucia, MD Professor and Vice Chair of Anatomic Pathology Chief of Genitourinary and Renal Pathology Dept. of
More informationMultiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy
2384 Multiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy Matthew R. Cooperberg, MD, MPH 1 Stephen J. Freedland, MD
More informationFocal Therapy is a Fool s Paradise : The whole prostate must be treated!
Focal Therapy is a Fool s Paradise : The whole prostate must be treated! Ofer Yossepowitch, MD Head, Department of Urology Tel Aviv Sourasky Medical Center Preaching against focal therapy in a focal therapy
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationSorveglianza Attiva update
Sorveglianza Attiva update Dr. Sergio Villa Dr. Riccardo Valdagni www.thelancet.com Published online August 7, 2014 http://dx.doi.org/10.1016/s0140-6736(14)60525-0 the main weakness of screening is a high
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationACTIVE SURVEILLANCE FOR PROSTATE CANCER
ACTIVE SURVEILLANCE FOR PROSTATE CANCER Dr. Michael J Metcalfe PGY-2 Department of Urological Sciences April 25, 2012 CASE RM 65 year old active Caucasian male, married. PSA= 7.0 T2a Gleason 3+3=6 2/6
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationORIGINAL ARTICLE. Ja Hyeon Ku 1, Kyung Chul Moon 2, Sung Yong Cho 1, Cheol Kwak 1 and Hyeon Hoe Kim 1
(2011) 13, 248 253 ß 2011 AJA, SIMM & SJTU. All rights reserved 1008-682X/11 $32.00 www.nature.com/aja ORIGINAL ARTICLE Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue
More informationExternal validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer
External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer Mathieu Roumiguié, Jean-Baptiste Beauval, Thomas Filleron*,
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
An Exploration of Risk Stratification for Active Surveillance and Androgen Deprivation Therapy Side Effects for Prostate Cancer Utilizing Data From the Surveillance, Epidemiology, and End Results Database
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationClinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Pathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications
More informationInt. J. Cancer: 120, (2006)
Int. J. Cancer: 120, 170 174 (2006) ' 2006 Wiley-Liss, Inc. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More informationProstate Cancer Who needs active surveillance?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller Prostate Cancer Who needs active surveillance? Klinische und molekulare Charakterisierung des Hoch-Risiko-Prostatakarzinoms.
More informationNational Trends in the Management of Low and Intermediate Risk Prostate Cancer in the United States
National Trends in the Management of Low and Intermediate Risk Prostate Cancer in the United States Adam B. Weiner, Sanjay G. Patel, Ruth Etzioni and Scott E. Eggener* From the Pritzker School of Medicine
More informationUse of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer {
Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer { (2003) 6, 39 44 ß 2003 Nature Publishing Group All rights reserved 1365 7852/03 $25.00 www.nature.com/pcan
More informationResearch Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer
Hindawi BioMed Research International Volume 2017, Article ID 9858923, 6 pages https://doi.org/10.1155/2017/9858923 Research Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy
More informationProstate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017
Prostate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017 Relevant Disclosures Advisory role, ownership interest, previous unrestricted grant
More informationPre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest
Pre-test Matthew R. Cooperberg, MD, MPH UCSF 40 th Annual Advances in Internal Medicine Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest 1. I do not offer routine PSA screening, and
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationPCa Commentary. Executive Summary: The "PCa risk increased directly with increasing phi values."
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2490 www.seattleprostate.com PCa Commentary Volume 77 September October 2012 CONTENT Page The Prostate 1 Health Index Active Surveillance 2 A
More informationAJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center
AJCC Cancer Staging 8 th Edition Prostate Chapter 58 Judd W Moul, MD, FACS Executive Committee, AJCC Professor and Director, Duke Prostate Center Duke University Durham, North Carolina Validating science.
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationProstate Biopsy in 2017
Prostate Biopsy in 2017 Bob Djavan, MD, PhD Professor and Chairman, Department of Urology, Rudolfinerhaus Foundation Hospital,Vienna, Austria Director Vienna Urology foundation Board member Scientific
More informationNIH Public Access Author Manuscript Clin Genitourin Cancer. Author manuscript; available in PMC 2015 October 01.
NIH Public Access Author Manuscript Published in final edited form as: Clin Genitourin Cancer. 2014 October ; 12(5): e181 e187. doi:10.1016/j.clgc.2014.02.008. The Impact of Differing Gleason Scores at
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationOncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.9.587 Urological Oncology Oncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy Yi-Hsueh
More informationActive Surveillance for Intermediate Risk Prostate Cancer
Active Surveillance for Intermediate Risk Prostate Cancer Eric Wallen, M.D., FACS Professor Department of Urology The University of North Carolina at Chapel Hill Disclosures: None Objectives Understand
More informationLocal Recommendations for Active Surveillance of Prostate Cancer
February 15 Local Recommendations for Active Surveillance of Prostate Cancer Chris Dawson Urology Lead Clinician February 2015 www.pchurology.co.uk Summary and Recommendations 1. There is no single set
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationDepartment of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara , Japan 2
Advances in Urology Volume 2012, Article ID 204215, 7 pages doi:10.1155/2012/204215 Research Article Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent
More informationA Genomic Approach to Active Surveillance
A Genomic Approach to Active Surveillance Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Cleveland Clinic Disclosures
More informationResearch Article Higher Prostate Weight Is Inversely Associated with Gleason Score Upgrading in Radical Prostatectomy Specimens
Advances in Urology Volume 2013, Article ID 710421, 7 pages http://dx.doi.org/10.1155/2013/710421 Research Article Higher Prostate Weight Is Inversely Associated with Gleason Score Upgrading in Radical
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationA Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy
168) Prague Medical Report / Vol. 112 (2011) No. 3, p. 168 176 A Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationPredictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
More informationPREDICTION OF PROSTATE CANCER PROGRESSION
EVALUATION OF PROSTAE SPECIFIC ANTIGEN (PSA) KINETICS IN PREDICTION OF PROSTATE CANCER PROGRESSION by Dongyu Zhang A thesis submitted to Johns Hopkins University in conformity with the requirements for
More informationDo all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database
Do all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database Sean Fischer*, Daniel Lin, Ross M. Simon*, Lauren E. Howard, William J. Aronson **,
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More information